AMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022

Rhea-AI Summary

Amgen will host a webcast for investors on August 8, 2022, at 12:00 p.m. ET, during the IASLC 2022 World Conference on Lung Cancer. David M. Reese, M.D., will present data on LUMAKRAS® (sotorasib) used alongside immunotherapy and a SHP2 inhibitor for treating non-small cell lung cancer, plus findings on tarlatamab for small cell lung cancer. The webcast will be available for replay for 90 days post-event. More details can be found on Amgen's website.

THOUSAND OAKS, Calif., Aug. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) at 12:00 p.m. ET on Monday, Aug. 8, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will discuss the data being presented on LUMAKRAS^® (sotorasib) in combination with immunotherapy and in combination with a SHP2 inhibitor in non-small cell lung cancer, as well as tarlatamab data in small cell lung cancer.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.  

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.  

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index.  In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

CONTACT: Amgen, Thousand Oaks
Jessica Akopyan, 805-447-0974 (media) 
Megan Fox, 805-447-1423 (media)
Arvind Sood, 805-447-1060 (investors) 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-webcast-investor-meeting-at-wclc-2022-301598360.html

SOURCE Amgen

FAQ

What is the date and time of Amgen's webcast call for investors?

Amgen's webcast call for investors is scheduled for August 8, 2022, at 12:00 p.m. ET.

What topics will be discussed during the Amgen webcast?

The webcast will cover data on LUMAKRAS® (sotorasib) in combination with immunotherapy and a SHP2 inhibitor, as well as tarlatamab data in small cell lung cancer.

Where can I find the Amgen webcast and its details?

The webcast and details can be found on Amgen's official website under the Investors section.

How long will the Amgen webcast be available for replay?

The Amgen webcast will be available for replay for at least 90 days after the event.

Who will present at Amgen's webcast during the WCLC 2022?

Dr. David M. Reese, executive vice president of Research and Development at Amgen, will present at the webcast.